New anti-epileptic drugs for the 21st century (Q34182061)

31 July 2017

1 reference

title

New anti-epileptic drugs for the 21st century (English)

1 reference

31 July 2017

McCabe PH

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

1

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

633-674

1 reference

Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

New formulations of drugs in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Lamotrigine in typical absence epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Lamictal (lamotrigine) monotherapy for typical absence seizures in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Safety of long-term lamotrigine in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Topiramate monotherapy for partial onset seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

A pilot study of topiramate in the treatment of infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Zonisamide in epilepsy: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Treatment of infantile spasms with zonisamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Dose-Response Study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Symptomatic and asymptomatic visual loss in patients taking vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Role of vigabatrin and lamotrigine in treatment of childhood epileptic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Myoclonic status epilepticus following high-dosage lamotrigine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Nonconvulsive status epilepticus in two patients receiving tiagabine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Antiepileptic drugs as a cause of worsening seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Lamotrigine for the treatment of bipolar disorder: a clinical case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Use of topiramate, a new anti-epileptic as a mood stabilizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

A mechanistic approach to antiepileptic drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Cost of epilepsy in the United States: a model based on incidence and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Payer costs of patients diagnosed with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

Double-Blind, Placebo-Controlled, Lamotrigine in Treatment-Resistant Generalised Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.1.4.633

21 January 2018

Identifiers

DOI

10.1517/14656566.1.4.633

1 reference

31 July 2017

1 reference